Establishment Labs (ESTA) Stock Price, News & Analysis

Company Overview

Establishment Labs Holdings Inc. is a medical technology company focused on developing, manufacturing and commercializing products for breast aesthetics and reconstruction. Founded in 2004 and headquartered in Alajuela, Costa Rica, the company serves plastic surgeons, healthcare providers and patients in markets around the world.

Its portfolio is centered on the Motiva line of breast implants, including implants designed for cosmetic augmentation and reconstructive procedures. Establishment Labs also develops related technologies and products, including tissue expanders and surgical systems, as well as Mia Femtech, a minimally invasive breast-enhancement procedure and platform.

The company operates internationally through direct sales and distribution partnerships. Establishment Labs was founded by Juan José Chacón-Quesada, who serves as its chief executive officer and has led the company’s development of breast-implant and surgical technologies.

Key Stats

• Today's Range: $68.32 to $70.14
• 50-Day Range: $69.30 to $95.65
• 52-Week Range: $37.37 to $97.59
• Volume: 238,504 shs
• Average Volume: 328,248 shs
• Market Capitalization: $2.07 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $100.25
• Consensus Rating: Moderate Buy

Establishment Labs Stock Analysis - MarketRank™

Establishment Labs scored higher than 57% of companies evaluated by MarketBeat, and ranked 378th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Establishment Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Establishment Labs has a consensus price target of $100.25, representing about 44.7% upside from its current price of $69.30.

Amount of Analyst Coverage

Establishment Labs has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Establishment Labs are expected to grow in the coming year, from ($1.15) to $0.01 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Establishment Labs is -52.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Establishment Labs is -52.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Establishment Labs has a P/B Ratio of 85.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.39% of the float of Establishment Labs has been sold short.

Short Interest Ratio / Days to Cover

Establishment Labs has a short interest ratio ("days to cover") of 12.22, which indicates bearish sentiment.

Change versus previous month

Short interest in Establishment Labs has recently increased by 7.25%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Establishment Labs does not currently pay a dividend.

Dividend Growth

Establishment Labs does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: N/A

News Sentiment

Establishment Labs has a news sentiment score of 1.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

Search Interest

2 people have searched for ESTA on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Establishment Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.99% of the stock of Establishment Labs is held by insiders.

Percentage Held by Institutions

72.91% of the stock of Establishment Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:ESTA
• CIK: 1688757
• Web: www.establishmentlabs.com
• Phone: (062) 434-2400
• Fax: N/A
• Employees: 1,004
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Establishment Labs: $100.25
• High Price Target: $117.00
• Low Price Target: $90.00
• Potential Upside/Downside: +44.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$51.06 million
• Net Margins: -15.82%
• Pretax Margin: -19.31%
• Return on Equity: -196.69%
• Return on Assets: -10.73%

Debt

• Debt-to-Equity Ratio: 12.11
• Current Ratio: 3.84
• Quick Ratio: 2.52

Sales & Book Value

• Annual Sales: $211.08 million
• Price / Sales: 9.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.81 per share
• Price / Book: 85.56

Miscellaneous

• Outstanding Shares: 29,800,000
• Free Float: 26,825,000
• Market Cap: $2.07 billion
• Optionable: Optionable
• Beta: 1.05